Alpha Cognition INC 8-K filings

Alpha Cognition Inc. has amended its previous filing to confirm the committee assignments for newly appointed director Bethany Sensenig.

Alpha Cognition Inc. has appointed biopharmaceutical industry veteran Bethany Sensenig to its Board of Directors.

Alpha Cognition Inc. has entered into a settlement agreement to resolve future payment obligations related to the Memogain Asset Purchase Agreement.

Alpha Cognition Inc. announced the dates for its 2026 Annual General Meeting of Shareholders and the associated record date.

Alpha Cognition Inc. announced its fiscal year 2025 financial and operational results, highlighting significant commercial momentum for its Alzheimer's treatment, ZUNVEYL, and a strong cash position.

Alpha Cognition Inc. announced that director Len Mertz will not seek re-election at the company's 2026 annual meeting.

Alpha Cognition Inc. announced the grant of restricted stock units, stock options, and performance share units to its named executive officers under its 2025 Stock and Incentive Plan.

Alpha Cognition Inc. announced a change in its independent registered public accounting firm from Manning Elliott LLP to CBIZ CPAs P.C. due to its relocation to Texas.

Alpha Cognition Inc. has appointed CBIZ CPAs P.C. as its new independent registered public accounting firm, replacing Manning Elliott LLP, following its relocation to Texas.

Alpha Cognition Inc. successfully priced an oversubscribed public offering of common shares and pre-funded warrants, raising approximately $35 million to accelerate the commercial launch of ZUNVEYL.

Alpha Cognition Inc. has established an At-the-Market Offering Agreement with H.C. Wainwright & Co., LLC, enabling the sale of up to $75.0 million in common shares.

Alpha Cognition Inc. announced that its stockholders approved the 2025 Stock Incentive Plan, elected six directors, and ratified Manning Elliot LLP as its independent auditor at the annual meeting held on June 19, 2025.

Alpha Cognition Inc. reports the departure of John Havens from the Board of Directors and the appointment of Robert Wills, Ph.D., effective April 7, 2025.

Alpha Cognition Inc. unveils its 2025 compensation packages for executives and directors, aiming for the 50th percentile compared to a peer group of similar companies.

Alpha Cognition Inc. issued warrants to purchase 34,196 common shares to underwriters as part of a recent agreement.

Alpha Cognition Inc. successfully completed a public offering, raising approximately $46.15 million to support the commercialization of ZUNVEYL and further research and development.

Alpha Cognition has executed a 1-for-25 reverse stock split to comply with Nasdaq's minimum share price requirements, effective November 5, 2024.

Alpha Cognition Inc. has appointed Henry Du as interim Chief Financial Officer, effective October 21, 2024, following the resignation of Jay Yoo.

Alpha Cognition Inc. has appointed Jay Yoo as its interim Principal Accounting and Financial Officer, effective October 2, 2024, following the departure of Don Kalkofen.

Alpha Cognition Inc. amended its articles to increase the quorum requirement for shareholder meetings to 33 1/3% and held its annual meeting where all directors were re-elected and proposals were passed.

Alpha Cognition Inc. has entered into a securities purchase agreement to issue senior convertible notes and warrants, raising $4.545 million in capital.

Alpha Cognition Inc. has entered into a securities purchase agreement to issue senior convertible notes and warrants for gross proceeds of $4.545 million.

Alpha Cognition Inc. has scheduled its annual general meeting for September 27, 2024, and is proposing to increase the quorum requirement for shareholder meetings.

Alpha Cognition Inc. reports the resignation of its Chief Financial Officer, Don Kalkofen, effective October 1, 2024, with a transition plan in place.

Alpha Cognition reports FDA approval for ZUNVEYL, a new Alzheimer's treatment, alongside its second quarter 2024 financial results.

Alpha Cognition Inc.'s board of directors has increased the quorum requirement for shareholder meetings from 5% to 33 1/3% of outstanding shares, effective immediately, to support its proposed Nasdaq listing.

Alpha Cognition's oral therapy, ZUNVEYL, has received FDA approval for treating mild-to-moderate Alzheimer's disease, marking the second oral treatment approved this decade.

Alpha Cognition has reached an agreement with Spartan Capital Securities, modifying their existing investment banking agreement to facilitate a public offering led by Alliance Global Partners/A.G.P.